Page 16 - Mylan EpiPen

In a company statement, Bresch said: "We recognize the

significant burden on patients from continued, rising

insurance premiums and being forced increasingly to pay

the full list price for medicines at the pharmacy counter.

Patients deserve increased price transparency and

affordable care, particularly as the system shifts significant

costs to them. However, price is only one part of the

problem that we are addressing with today's actions. All
involved must also take steps to help meaningfully address

the U.S. healthcare crisis, and we are committed to do our
part to drive change in collaboration with policymakers,

payors, patients and healthcare professionals." Source:

http://Newsroom.Mylan.com

In December 2016, Mylan

rolled out an authorized

generic version of the

EpiPen. But this with the

negative publicity impacted

on Mylan’s share price. To

mitigate this Mylan announced that it would help reduce the

out-of-pocket cost of EpiPens by extending its discount

programme to more uninsured and underinsured patients.

How much individuals pay for an EpiPen prescription can

depend on their insurance coverage. But the company did
not reduce the list price of EpiPens.

Nevertheless, Mylan shareholders still took a hit. Especially

as Kaleo's AUVI-Q was re-released in mid-February 2017,
and CVS announced that it would stock the generic version

of Adrenaclick, a $110 EpiPen alternative.